Human papillomavirus E6 oncogene DNA sequence (HPV E6 DNA)

The Human papillomavirus (HPV) E6 oncogene DNA sequence is a critical genomic component of high-risk HPV types, such as HPV-16 and HPV-18, which are the primary causative agents of cervical and other mucosal cancers (National Cancer Institute, 2023). This DNA sequence encodes the E6 oncoprotein, a multifunctional protein that facilitates malignant transformation by inducing the degradation of the tumor suppressor protein p53 via the ubiquitin-proteasome pathway (Scheffner et al., 1990; PubMed ID: 2174350). By targeting the E6 DNA sequence directly, therapeutic interventions aim to permanently disrupt or silence the production of the E6 protein, thereby restoring the cell's natural apoptotic pathways and halting tumor growth (Kennedy et al., 2014; PubMed ID: 24827156). Current experimental strategies include the use of CRISPR/Cas9 gene editing, antisense oligonucleotides, and RNA interference to specifically recognize and neutralize the viral sequence (Zhen et al., 2014; PubMed ID: 25353350). Because the E6 gene is constitutively expressed in HPV-positive cancer cells but absent in healthy human cells, it represents a highly specific target for precision oncology (StatPearls, 2023). Successful targeting of this sequence has the potential to treat established HPV-driven malignancies and prevent the progression of pre-cancerous lesions.

Other names

HPV E6 geneHuman papillomavirus E6 geneE6 open reading frameHPV16 E6 DNAHPV18 E6 DNA

Therapeutic agents targeting the HPV E6 DNA sequence typically utilize sequence-specific recognition to induce double-strand breaks (via CRISPR/Cas9 or TALENs) or promote mRNA degradation (via siRNA or ASOs), leading to the loss of E6 oncoprotein expression and subsequent stabilization of p53 (Int J Mol Sci, 2021; PubMed ID: 33804485).